Clinical trials: Depression Symptom
Coronary Heart Disease
Stress Management and Biomarkers of Risk in Cardiac Rehabilitation
The purpose of this study is to assess the extent to which combining exercise and stress management training (SMT) is more effective at improving biomarkers in vulnerable cardiac patients compared to exercise-based cardiac…
- Trial name
- ENHANCED (NCT00981253)
- Testing
- SMT-enhanced Cardiac Rehabilitation, Standard Cardiac Rehabilitation
- Where
- 2 sites in United States
- Volunteers
- 164 people
- Sponsor
- Duke University
Major Depressive Disorder
Reward Function and Therapy for Late-Life Depression
The goal of this study is to learn about changes in the brain that occur during Engage, a psychotherapy for depression in older adults, and how they may differ from changes that occur during supportive therapy.
- Trial name
- NCT03688139
- Testing
- Engage Therapy, Supportive Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER).
- Trial name
- NCT00401726
- Testing
- Venlafaxine ER, Dialogues Time to Talk Program
- Where
- 44 sites in United States
- Volunteers
- 537 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Burnout, Professional, Anxiety
Feasibility of a Yoga- and Mindfulness-Based Intervention for Resident Physicians
The investigators aim to initiate and complete the first investigation of the effect of a yoga-based program on resident physicians' psychological health using a randomized controlled trial to assess feasibility of the program in…
- Conditions
- Burnout, Professional, Anxiety, Depression, Stress
- Trial name
- NCT03687450
- Testing
- RISE yoga-based program
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02158533
- Testing
- High Dose ALKS 5461, Low Dose ALKS 5461
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 385 people
- Sponsor
- Alkermes, Inc.
Head and Neck Cancer, Head and Neck Cancers
Mental Health App for Cancer Survivors Study
The goal of this clinical trial is to adapt a mental health digital app to treat depression among head and neck cancer patients and survivors.
- Conditions
- Head and Neck Cancer, Head and Neck Cancers, Depression
- Trial name
- MACS (NCT06472726)
- Testing
- IONA Mind app
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Wisconsin, Madison
Arthritis, Diabetes
Can Mental Health Chatbots Help Chronic Disease Populations?
Past research has shown that patients suffering from chronic health conditions tend to experience high levels of negative mental health symptoms (e.g., depression).
- Conditions
- Arthritis, Diabetes, Depression, Anxiety
- Trial name
- NCT04620668
- Testing
- Wysa
- Where
- Canada
- Volunteers
- 79 people
- Sponsor
- Luke MacNeill
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Symptoms, Diabetes Mellitus
Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression
This work is supported by the "Kompetenznetz Diabetes mellitus (Competence Network for Diabetes mellitus)" funded by the Federal Ministry of Education and Research (FKZ 01GI0809).
- Trial name
- NCT01009138
- Testing
- Diabetes-Specific CBT (DS-CBT), Standard Diabetes Education
- Where
- Germany
- Volunteers
- 214 people
- Sponsor
- Forschungsinstitut der Diabetes Akademie Mergentheim
Depression
Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs
The purpose of this study is to determine the effectiveness of a brief cognitive behavioral therapy (bCBT) intervention for Veterans with depression delivered by mental health providers located at VA Community Based Outpatient…
- Trial name
- MyBriefCBT (NCT02466126)
- Testing
- bCBT
- Where
- 2 sites in United States
- Volunteers
- 189 people
- Sponsor
- VA Office of Research and Development
Depression, HIV
Depression Therapy to Improve Cardiovascular Risk in HIV
This trial will determine if depression treatment will reduce cardiovascular risk in HIV-infected patients already receiving HIV treatments.
- Trial name
- NCT02309372
- Testing
- Beating the Blues
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Indiana University
Major Depressive Disorder
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome
The purpose of this study is to examine whether neural-derived exosomal miRNAs are differentially expressed that are specific to suicidal ideation or behavior, and which by affecting specific miRNA targets and pathways, are…
- Trial name
- NCT02418195
- Testing
- ketamine
- Where
- United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Major Depressive Disorder
Does Dual Therapy Hasten Antidepressant Response?
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates…
- Trial name
- NCT00519428
- Testing
- escitalopram, bupropion extra long (XL), escitalopram + bupropion
- Where
- 2 sites in United States, Canada
- Volunteers
- 245 people
- Sponsor
- New York State Psychiatric Institute
Cocaine Dependence, Depression
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
This research study is being done to look at the safety of the medication Mirtazapine (Remeron) in people who have cocaine dependence and depression. Hypotheses I.
- Trial name
- NCT00322309
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boston University
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Chronic Kidney Disease, Depression
Chronic Kidney Disease Antidepressant Sertraline Trial
This is a randomized double-blinded placebo-controlled trial to see if treatment with sertraline as compared with placebo tablets will improve depression symptoms in patients with chronic kidney disease who have not yet started…
- Trial name
- CAST (NCT00946998)
- Testing
- Sertraline
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- VA Office of Research and Development
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Heart Failure
Personalized Treatments for Depressive Symptoms in Patients With Advanced Heart Failure
We are doing this study to help patients, caregivers, and providers make decisions about how best to manage depressive symptoms in advanced heart failure.
- Trial name
- NCT03688100
- Testing
- Behavioral Activation Therapy, Medication Management
- Where
- United States
- Volunteers
- 494 people
- Sponsor
- Cedars-Sinai Medical Center
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.